Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
20 oct. 2022 16h05 HE
|
Plus Therapeutics Inc.
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) ...
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
19 oct. 2022 07h00 HE
|
Plus Therapeutics Inc.
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor...
Plus Therapeutics to Present at the ThinkEquity Conference
18 oct. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
06 oct. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month
05 oct. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
04 oct. 2022 07h15 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
22 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases...
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
12 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with...
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
06 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06,...